1. Home
  2. PLAG vs RNTX Comparison

PLAG vs RNTX Comparison

Compare PLAG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Planet Green Holdings Corp.

PLAG

Planet Green Holdings Corp.

HOLD

Current Price

$2.45

Market Cap

25.6M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLAG
RNTX
Founded
1986
2001
Country
United States
United States
Employees
6
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
30.0M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
PLAG
RNTX
Price
$2.45
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
264.5K
72.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
32.56
N/A
EPS
N/A
N/A
Revenue
$6,729,937.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$1.02
52 Week High
$4.49
$2.50

Technical Indicators

Market Signals
Indicator
PLAG
RNTX
Relative Strength Index (RSI) 44.01 49.55
Support Level $1.56 $1.06
Resistance Level $3.07 $1.29
Average True Range (ATR) 0.55 0.10
MACD -0.16 0.01
Stochastic Oscillator 17.03 61.36

Price Performance

Historical Comparison
PLAG
RNTX

About PLAG Planet Green Holdings Corp.

Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: